Navigation Links
Diatos Announces Positive Clinical Results for its DTS-201,Doxorubicin Prodrug Program

out any unexpected side effects," stated Jean-Pierre Delord, M.D., principal investigator from the anti-cancer center Claudius Regaud Institute in Toulouse, France. "In particular, no severe toxicity has been observed even after the administration of six cycles of the agent in this Phase I trial. Furthermore, we have observed some encouraging activity in normally chemo-resistant cancers."

DTS-201 was initially discovered by Pr Andre Trouet and his team at the Universite Catholique de Louvain, Belgium, and exclusive European rights were in-licensed from Medarex Inc. in April 2003 as a preclinical compound.

President and CEO of Diatos John Tchelingerian, Ph.D, added: "I am satisfied that Diatos continues to make substantial progress in its clinical development programs based on novel, targeted anti-cancer chemotherapies. The positive results from our Phase I study with DTS-201, particularly the encouraging signs of improved efficacy versus standard doxorubicin treatment, represent a significant milestone in the development of our product. Diatos is poised to initiate a Phase II study for DTS-201 in Europe soon, advancing what we believe is a next generation anthracycline for the benefit of cancer patients."

Notes to Editors:

About DTS-201

DTS-201 consists of doxorubicin, a marketed cytotoxic agent effective against a wide variety of solid tumors, conjugated to a proprietary peptide. The product was discovered in 1996 by Pr Andre Trouet and his team at the Universite Catholique de Louvain, Belgium and in-licensed from Medarex Inc in April 2003. DTS-201 is also known as Super-Leu-Dox or CPI-0004Na in the USA.

DTS-201 is a prodrug designed to preferentially deliver doxorubicin to tumors as opposed to normal tissues. It consists of the tetrapeptide N-succinyl-(beta)-alanyl-L-leucyl-L-alanyl-L-leucine covalently linked to the aminoglycoside portion of doxorubicin.

Peptide-based targeting of tumors is an attractive approach f
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:5/16/2008)...6 /- Memory Pharmaceuticals...ith several key development,programs at its R&D Da...ny,reported new clinical data for MEM 1414, its le...S activity in humans. In addition, the,Company has...date from its,5-HT6 antagonist program, and separa...
(Date:5/16/2008)... /- BioVex Inc, a biotechnology,compa...and infectious,disease, announced today that the a...ase II clinical trial of OncoVEX GM-CSF in advance...ican Society of Clinical Oncology,(ASCO) website l...abstract,which describes the data as of the submis...
(Date:5/16/2008)...al Biomarkers -- for Lung Cancer Diagnosis and, Id...er of Unknown Primary ... Types With High Sensitivity and, Specificity an...ancer Results of microRNA Signature to Identify T...eding 90% and Specificity of 99%, REHOVOT, Israel...
(Date:5/16/2008)...Statistically Significant Reductions in Selected ...tract to be published in 2008 Proceedings of the A...cal Oncology, SAN DIEGO, May 16 /PRNewswire-First...X ) announced today that, in a registrational bioe...statistically significant reduction,in general dis...
Breaking Medicine Technology:Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day 2Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day 3Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day 4BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 2BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 4Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 5Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 6ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 2ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 3ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 4ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 5Environment Energy and Ethics conference at UD Sept 21 23 1197 1Environment Energy and Ethics conference at UD Sept 21 23 1197 2Scientists highlight benefits of genetic research in sport but warn of ethical concerns 1194 1Scientists highlight benefits of genetic research in sport but warn of ethical concerns 1194 2Scientists highlight benefits of genetic research in sport but warn of ethical concerns 1194 3Salmon garnish points the way to green electronics 377 1Salmon garnish points the way to green electronics 377 2Salmon garnish points the way to green electronics 377 3Academy releases emergency preparedness tools to enable millions more people to shelter in place 1191 1Academy releases emergency preparedness tools to enable millions more people to shelter in place 1191 2Academy releases emergency preparedness tools to enable millions more people to shelter in place 1191 3Academy releases emergency preparedness tools to enable millions more people to shelter in place 1191 4
...udy shows intramuscular injection of peramivir for...nza virus infection and,inhibited virus replicatio...uenza during a pandemic, MEMPHIS, Tenn., May 01, 2...peramivir might offer humans significant protectio...5N1, according to,results of mouse studies conduct...
...ivotal phase III study in women with recurrent ova...GTON, May 01, 2007,/PRNewswire-FirstCall/ -- A new...tion of phenoxodiol, an investigational drug being...drug appears to,work by targeting a certain tumor-...s that selectively induce cancer cell death.,Pheno...
Other Medicine Technology:Peramivir Protects Mice From Lethal H5N1 Infection 2Peramivir Protects Mice From Lethal H5N1 Infection 3New Research Results Show That Investigational Drug Phenoxodiol,Targets Cancer Protein, Causing Cancer Cell Death 2New Research Results Show That Investigational Drug Phenoxodiol,Targets Cancer Protein, Causing Cancer Cell Death 3New Research Results Show That Investigational Drug Phenoxodiol,Targets Cancer Protein, Causing Cancer Cell Death 4New Research Results Show That Investigational Drug Phenoxodiol,Targets Cancer Protein, Causing Cancer Cell Death 5
(Date:5/16/2008)...s, WASHINGTON, May 16 /PRNewswire-USNewswire/ -- ...hnicians in the Greater Portland, Oregon and,Vanco...er contract as,Teamsters., "The Teamsters are ple...g contract that gives them job protection and a se...esident Jim Hoffa., The workers, both full-time a...
(Date:5/16/2008)...are medicine is in a precipitous decline, David C.... of Physicians (ACP), today joined with leading r... a call for comprehensive reforms to attract, recr...y care physicians. , During a panel discussion ... Dr. Dale and other panelists spoke about the chal...
(Date:5/16/2008)... $38 Million for Life-threatening,Disease, BETHES... in nearly,every state will raise funds for cystic...icipating in GREAT STRIDES, the largest national C...unced today., May is National Cystic Fibrosis Awa...g genetic disease that causes fatal lung infection...
(Date:5/16/2008)...oyed politicians - and economists, ORLANDO, Fla.... all,voters place health care at the top of their ...dgetary crunch means none of the health care plans...dates is likely to become,law anytime soon, says f...usting with Princeton University Health care Econo...
Breaking Medicine News(10 mins):Health News:ACP says major system reforms needed to improve the state of primary care medicine in the US 2Health News:GREAT STRIDES Walks for Cystic Fibrosis Slated for 47 States This Weekend 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 3
... Tata Consultancy Services (TCS) Tuesday announced...-based //Parkway Hospitals to provide and implemen...ccording to the deal, TCS will work with Parkway H...Hospital Management Solution (HMS) as per its spec...
...layer, is in the dock. The Canadian Football Leagu...d //for not disclosing the fact that he was infect... two women. According to an agreed list of admissi...h tested HIV positive and was informed about his i...
...ing a petition against a court ruling that seeks t...gs. // What makes this news significant is that it...n AIDS patient; a nightmare or a manageable crisis...t to patent a modified version of its drug Glivec ...
...biology at the University of New Hampshire and dir...tory, is available to discuss the science and// pu...es, also known as Norwalk and Norwalk-like viruses...ses of acute gastroenteritis in the United States ...
Other Medicine News:Health News:To Patent or Not-A Question of Life 2Health News:Sanitation and Science Prevent Norovirus Spread 2
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
Medicine Products: